Research programme: CNS therapeutics - Adamas PharmaceuticalsAlternative Names: ADS-8800; ADS-8801; ADS-9000
Latest Information Update: 07 Sep 2016
At a glance
- Originator Adamas Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Epilepsy
- Research CNS disorders
Most Recent Events
- 07 Sep 2016 Preclinical trials in Epilepsy in USA (unspecified route) prior to September 2016 (Adamas Pharmaceuticals pipeline, September 2016)